Why Biomarker Changes Do Not Establish Improved Sexual Function

Biomarker changes do not establish improved sexual function because a biomarker is a measurable biological characteristic rather than a direct measurement of a participant's sexual desire, subjective arousal, distress, satisfaction, sexual activity, or complete sexual experience. A hormone concentration, receptor-related signal, physiological response, or neural measurement may provide mechanistic evidence, but the relationship between that marker and a meaningful sexual-function endpoint must be demonstrated rather than assumed.

This distinction is fundamental when interpreting peptides in sexual-function research. Peptides may alter measurable signaling pathways or physiological variables without establishing that participants experienced a corresponding change in sexual function.

This article is provided for general educational purposes and explains research methods, endpoints, and evidence concepts associated with peptide sexual-function research. It does not establish the regulatory status of any specific InStrips product or determine whether a particular product is appropriate for any person.

A biomarker should therefore be described according to what was actually measured, why researchers selected it, how strongly it is connected to the endpoint of interest, and whether changes in that biomarker have been shown to predict a meaningful participant-reported or functional outcome.

What Is a Biomarker?

A biomarker is an objectively measured characteristic used to indicate a biological process, exposure, response, or another defined biological state.

Biomarkers relevant to peptide research may include:

• hormone concentrations
• peptide concentrations
• receptor-related measurements
• signaling molecules
• metabolic products
• physiological recordings
• imaging-derived measurements

These measurements can be scientifically useful without representing a direct sexual-function outcome.

Biomarker and Clinical Outcome Are Different Concepts

A biomarker describes biology.

A clinical or participant-experienced outcome may describe:

• how a participant feels
• how a participant functions
• sexual desire
• subjective arousal
• distress
• satisfaction
• pain

A biological change and an experienced outcome can be related, but the relationship must be established empirically.

Why Sexual Function Is Multidimensional

Sexual function includes multiple domains that may change independently.

These may include:

• desire
• subjective arousal
• genital response
• erectile function
• lubrication
• orgasm
• satisfaction
• distress

No single biomarker automatically summarizes all of these dimensions.

Hormone Concentrations Are Biomarkers

Hormones are commonly measured in reproductive and sexual-function research.

Researchers may examine:

• testosterone
• estradiol
• progesterone
• luteinizing hormone
• follicle-stimulating hormone
• prolactin
• other endocrine measurements

A change in a hormone concentration does not by itself establish a change in sexual desire or function.

Testosterone and Sexual-Function Interpretation

Testosterone may be examined in research involving sexual function, but one concentration does not determine an individual's sexual experience.

Interpretation may depend on:

• sex
• age
• binding proteins
• time of sampling
• assay method
• baseline endocrine status
• other biological and psychosocial factors

An increase in measured testosterone should therefore be reported as an endocrine change rather than as automatic evidence of increased libido.

Estradiol and Other Reproductive Hormones

Estradiol and other reproductive hormones can influence reproductive physiology, but their relationship with sexual-function domains is complex.

A concentration change does not directly reveal:

• sexual interest
• subjective arousal
• sexual satisfaction
• distress
• relationship context

Participant outcomes must be measured separately.

Luteinizing Hormone as a Research Marker

Some peptide research examines luteinizing hormone because the peptide interacts with reproductive endocrine signaling.

A change in luteinizing hormone may provide evidence that:

• a reproductive signaling pathway was engaged
• endocrine output changed
• the peptide had measurable biological activity under the study conditions

It does not independently establish an improvement in sexual desire, arousal, distress, or satisfaction.

Kisspeptin as an Example

Kisspeptin research illustrates the distinction between pathway engagement and sexual-function outcomes.

Kisspeptin can be studied through measurements involving:

• reproductive hormone signaling
• brain responses
• behavioral tasks
• participant-reported measures

Each layer answers a different scientific question.

Pathway Engagement Is Not a Complete Outcome

A peptide may produce a measurable response in its proposed biological pathway.

This may support evidence of:

• target engagement
• pharmacological activity
• downstream signaling
• dose-response relationships

Target engagement does not establish that the pathway change resulted in a meaningful sexual-function outcome.

Receptor Binding Is Not Sexual Function

Laboratory experiments may measure how strongly a peptide binds to a receptor.

Binding data can help characterize:

• affinity
• selectivity
• concentration-response relationships
• potential off-target interactions

Binding to a receptor does not independently establish what happens at whole-body exposure levels or how participants experience sexual function.

Receptor Activation Is Not an Outcome

A peptide may activate a receptor in a cellular assay.

This may lead to measurable changes in:

• second messengers
• intracellular signaling
• gene expression
• enzyme activity

These laboratory measurements are mechanistic evidence rather than direct clinical endpoints.

Cell-Signaling Changes

Cell studies may identify changes in signaling pathways after peptide exposure.

Interpretation requires consideration of:

• cell type
• peptide concentration
• exposure duration
• receptor expression
• assay conditions
• comparison controls

A cellular signal does not establish that the same concentration or biological effect occurs in human sexual-function research.

Blood Peptide Concentration Is an Exposure Biomarker

Researchers may measure peptide concentrations after administration.

This can provide information about:

• systemic exposure
• time to measurable concentration
• maximum concentration
• total exposure
• elimination

Detectable exposure establishes neither target engagement nor a sexual-function outcome by itself.

Higher Exposure Is Not Automatically Better

A larger peptide concentration or area under the concentration-time curve does not automatically indicate a larger favorable outcome.

Higher exposure may be associated with:

• greater target engagement
• no additional response
• greater variability
• different adverse-event patterns

The exposure-response relationship must be studied directly.

Pharmacodynamic Biomarkers

A pharmacodynamic biomarker measures a biological response occurring after exposure.

Examples could include:

• hormonal changes
• receptor-linked signaling
• vascular responses
• physiological changes

A pharmacodynamic response can show that something biological changed without establishing whether the change was beneficial or meaningful to participants.

Genital Blood Flow as a Physiological Measure

Sexual-function research may measure genital vascular responses.

Examples include changes related to:

• vaginal blood volume
• vaginal pulse amplitude
• penile blood flow
• erectile rigidity
• genital temperature

These measurements should not automatically be described as direct measures of subjective arousal or desire.

Physiological Arousal and Subjective Arousal Can Diverge

Research has shown that subjective and genital measures of sexual arousal are related but not perfectly concordant.

A participant may show:

• a measurable genital response with limited subjective arousal
• subjective arousal without a proportional genital response
• different patterns depending on the stimulus

Physiological arousal therefore cannot substitute automatically for participant-reported arousal.

Brain-Imaging Signals as Biomarker-Like Measures

Functional brain imaging can measure changes in BOLD signal or connectivity during experimental tasks.

These measurements may help investigate:

• sexual cue processing
• reward
• motivation
• emotion
• attention

They do not directly measure the participant's sexual experience.

Why Imaging Cannot Replace Functional Endpoints

A brain region may respond differently during a peptide experiment without a corresponding change in participant-reported sexual function.

The limitations of these measurements are discussed in how brain imaging is used in peptide sexual-function studies.

Imaging and patient-reported outcomes should be interpreted as complementary rather than interchangeable evidence.

Autonomic Biomarkers

Researchers may measure physiological variables associated with autonomic activation.

Examples include:

• heart rate
• blood pressure
• skin conductance
• respiration
• pupil responses

These measurements are nonspecific because they can change during stress, attention, excitement, fear, physical activity, and many other conditions.

A Biomarker May Be Proximal or Distal

Some biomarkers occur relatively close to the peptide's molecular target, while others occur further downstream.

A possible sequence might include:

• peptide exposure
• receptor engagement
• cell signaling
• endocrine response
• neural response
• participant experience

Evidence at an early step does not establish every later step.

Biological Plausibility Is Not Outcome Evidence

A mechanistic pathway may make a proposed effect biologically plausible.

Plausibility does not independently demonstrate:

• the magnitude of an outcome
• the frequency of an outcome
• the duration of an outcome
• clinical relevance
• participant-perceived change

Mechanism can support a hypothesis that must still be tested.

Correlation Between Biomarker and Outcome

Researchers may examine whether biomarker values correlate with sexual-function scores.

A correlation means that the measurements vary together statistically.

It does not establish:

• that the biomarker caused the outcome
• that changing the biomarker will change the outcome
• that another variable does not influence both
• that the association applies outside the study population

Strong Correlation Is Still Not Causation

Even a strong statistical relationship can arise because two variables share another underlying cause.

Potential influences in sexual-function research may include:

• age
• hormonal status
• general health
• medications
• psychological state
• relationship context

Study design determines how strongly causal conclusions can be considered.

Temporal Association

A biomarker may change before, during, or after a reported sexual-function outcome.

Temporal ordering can contribute to causal reasoning, but it does not independently establish causation.

Researchers may also need evidence involving:

• randomization
• dose-response relationships
• replication
• mechanistic consistency
• control conditions

Surrogate Endpoints

A surrogate endpoint is a biomarker or other measure used in place of a direct clinical outcome when supported for that purpose.

Not every biomarker qualifies as a validated surrogate.

Validation requires evidence that the surrogate reliably predicts the outcome of interest in the relevant context.

Why Surrogate Validation Is Context-Specific

A biomarker may predict an outcome in one disease, population, intervention class, or research setting without being valid in another.

Researchers may need to consider:

• population
• intervention mechanism
• outcome
• duration
• biological pathway

Calling a measurement a surrogate does not automatically establish its validity.

Intermediate Endpoints

An intermediate endpoint may lie between a biomarker and a final participant-experienced outcome.

For example, a physiological change may be closer to sexual function than a cellular signaling marker while still not capturing:

• desire
• distress
• satisfaction
• daily-life function

The evidence level should reflect what the endpoint actually measures.

Biomarker Variability

Biomarkers may vary naturally within the same participant.

Sources of variation may include:

• time of day
• food intake
• sleep
• stress
• menstrual or hormonal stage
• physical activity
• sample handling

A single measurement can therefore provide an incomplete estimate of a participant's typical value.

Assay Variability

Laboratory measurements also contain analytical variation.

Results may depend on:

• assay platform
• calibration
• reference standards
• sample storage
• cross-reactivity
• lower detection limits
• laboratory procedures

Small biomarker differences should be interpreted relative to assay performance.

Endogenous and Administered Peptides

Some research peptides are identical or similar to endogenous molecules.

Analytical methods may need to distinguish:

• naturally occurring peptide
• administered peptide
• peptide fragments
• modified forms
• cross-reacting molecules

An increase in total measured signal does not necessarily identify its source unless the assay can distinguish these forms.

Baseline Differences

Participants may enter a study with different biomarker concentrations.

Researchers may analyze:

• absolute post-administration values
• change from baseline
• percentage change
• area under the response curve

Different analytical approaches can produce different impressions of the same underlying data.

Large Percentage Changes Can Be Misleading

A large percentage change may occur when the baseline value is small.

Interpretation should therefore consider:

• absolute values
• relative changes
• confidence intervals
• assay variability
• biological significance

The largest percentage does not automatically represent the most meaningful biological effect.

Group Averages Can Conceal Individual Variation

An average biomarker response may combine very different individual patterns.

Some participants may show:

• large increases
• small increases
• no measurable change
• decreases

Group means should therefore be interpreted alongside measures of variability and individual data when available.

Statistical Significance Does Not Establish Sexual-Function Meaning

A statistically identifiable biomarker difference indicates that the observed data meet the assumptions and threshold of the selected statistical method.

It does not establish:

• a participant-perceived difference
• clinical importance
• functional relevance
• duration
• causation outside the study design

Multiple Biomarkers

Studies may measure many hormones, signaling molecules, imaging regions, or physiological variables simultaneously.

Testing many measurements increases the possibility of finding a difference by chance.

Researchers may therefore use:

• predefined biomarker hypotheses
• statistical correction
• replication
• independent validation

One favorable biomarker among many null findings should not be isolated without context.

Exploratory Biomarkers

Early studies may use biomarkers to generate hypotheses.

Exploratory findings may identify:

• candidate pathways
• possible responder patterns
• new biological relationships
• future study endpoints

Exploratory findings require confirmation before being treated as established relationships.

Biomarkers in Animal Research

Animal models may show peptide-related changes in hormones, receptors, neural signaling, or sexual behavior.

Translation may be limited by differences in:

• species biology
• receptor distribution
• peptide metabolism
• behavioral interpretation
• experimental conditions

An animal biomarker change should not automatically be presented as a human sexual-function outcome.

Biomarkers in Cell Research

Cell systems may be useful for identifying molecular responses.

They do not reproduce:

• whole-body pharmacokinetics
• brain networks
• relationships
• subjective experience
• complex hormonal feedback
• human sexual behavior

A cellular finding should remain identified as preclinical mechanistic evidence.

Participant-Reported Outcomes Remain Necessary

When the research question concerns how participants feel or function, direct participant measurement is required.

Researchers may use PRO instruments to assess:

• desire
• subjective arousal
• distress
• satisfaction
• other experienced sexual-function domains

A biomarker cannot replace a fit-for-purpose participant-reported outcome merely because it is objective.

Objective Does Not Mean More Relevant

Objective measurements can reduce some forms of reporting bias, but relevance depends on the research question.

If the question is whether participants experience greater sexual desire, a validated desire measure may be more directly relevant than:

• a hormone concentration
• a BOLD signal
• a receptor assay
• genital blood flow

Measurement objectivity and endpoint relevance are separate qualities.

Biomarkers and Adverse Effects

A biomarker change may also represent an unwanted physiological effect rather than a favorable outcome.

Researchers may monitor:

• blood pressure
• heart rate
• laboratory chemistry
• hormone concentrations
• immune markers

The direction of a numerical change does not determine whether it is favorable.

Benefit-Risk Interpretation

Even a biomarker linked with a desired pathway should be considered alongside:

• participant-reported outcomes
• adverse events
• exposure
• duration
• uncertainty
• product-specific evidence

A pathway response alone cannot establish an overall favorable benefit-risk profile.

What Biomarker Research Can Establish

Well-designed biomarker research may provide evidence about:

• peptide exposure
• target engagement
• endocrine responses
• physiological responses
• neural-processing changes
• possible mechanisms
• relationships with other measured outcomes

The conclusion should remain limited to the biological measurement studied.

What Biomarker Research Does Not Establish

A biomarker change does not independently establish:

• improved sexual desire
• improved subjective arousal
• reduced sexual distress
• greater sexual satisfaction
• increased sexual activity
• complete sexual-function improvement
• a universal peptide-related outcome

Reading Biomarker Research

Readers may ask:

• What exactly was measured?
• Is the marker related mechanistically or validated as a surrogate?
• Was a participant-reported outcome also measured?
• Did biomarker and functional outcomes change together?
• How variable was the biomarker?
• Was the assay validated?
• Was the analysis predefined?
• Has the biomarker-outcome relationship been replicated?

The FDA guidance addressing sexual-interest, desire, and arousal research emphasizes direct assessment of relevant sexual-function concepts rather than assuming that biological measurements alone establish participant-experienced outcomes.

Final Perspective

Biomarkers are valuable tools for investigating peptide exposure, signaling, endocrine responses, physiology, and possible mechanisms.

Their scientific usefulness does not make them substitutes for direct sexual-function endpoints.

Accurate peptide research distinguishes target engagement from participant experience, correlation from causation, and mechanistic plausibility from demonstrated function. A hormone concentration, receptor signal, genital physiological response, or brain-imaging change is evidence about that biological measurement, not proof that sexual function improved.